Immunological Profiling of IgM and IgG in Responses to COVID-19 Vaccination in Iraq

Abstract

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has stimulated extensive research into the immune responses elicited by infection and vaccination. This study aimed to evaluate the efficacy of two widely administered SARS-CoV-2 vaccines, Pfizer and Sinopharm, by measuring humoral immunity through immunoglobulin M (IgM) and G (IgG) levels in individuals who completed a two-dose vaccination regimen. Three hundred Iraqi adults aged 22-58 participated in the study, which assessed immune responses to Pfizer and Sinopharm COVID-19 vaccines over the first three months post-vaccination. The findings revealed variations in immunoglobulin responses between the two vaccines, with both Pfizer and Sinopharm demonstrating elevated IgM and IgG levels. These results highlight the differential effectiveness of various vaccines in inducing immune responses, providing valuable insights for public health strategies in managing COVID-19 vaccination programs.